Cidara Therapeutics completes enrollment of Phase 2b NAVIGATE trial

Cidara Therapeutics (CDTX) announced it has reached full planned enrollment of 5,000 subjects in the Phase 2b NAVIGATE trial across clinical sites in the US and UK. The trial is designed to evaluate the efficacy and safety of CD388, the company’s DFC for the pre-exposure prophylaxis of seasonal influenza. “Completing the NAVIGATE study at the beginning of the northern hemisphere flu season was a critical milestone to evaluate the efficacy and safety of CD388 as a potential long-acting, universal influenza preventative,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Thanks to the efforts of our investigators and clinical teams, we are now well-positioned to advance the study as this year’s flu season unfolds.”